• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks

    MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166

    Gabrielle Lakusta
    Jan. 22, 2019 08:33AM PST
    Pharmaceutical Investing

    MediciNova a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the …

    MediciNova a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

    As quoted in the press release:

    Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than November 2035. The allowed claims cover a method of treating a patient diagnosed with ALS, as well as a wide range of other neurodegenerative diseases, with the combination of MN-166 (ibudilast) and riluzole.  Other neurodegenerative diseases covered by this patent include Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, Lewy body disease, motor neuron disease, spinal muscular atrophy, myelopathy, traumatic brain injury, spinal cord injury, and many others.

    MediciNova was previously granted a U.S. patent which covers the use of MN-166 (ibudilast) as monotherapy for the treatment of amyotrophic lateral sclerosis (ALS) and it expires no earlier than January 2029.  MediciNova was previously granted three U.S. patents which cover the use of MN-166 (ibudilast) as monotherapy for the treatment of progressive multiple sclerosis including both primary progressive multiple sclerosis and secondary progressive multiple sclerosis.  The first one of these patents expires no earlier than November 2029 and patent term restoration would add 5 years once MN-166 (ibudilast) is approved for progressive multiple sclerosis, extending the patent expiration to November 2034.

    Click here to read the full press release.

    amyotrophic lateral sclerosisnasdaq:mnov
    The Conversation (0)

    Go Deeper

    AI Powered
    Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

    Top 5 Small-cap Pharma Stocks of 2025

    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    Ă—